(1) Chronic hepatitis B. (2) Corrections to AASLD guidelines on chronic hepatitis B.

GUIDELINE TITLE
(1) Chronic hepatitis B. (2) Corrections to AASLD guidelines on chronic hepatitis B.

BIBLIOGRAPHIC SOURCE(S)
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 Feb;45(2):507-39. [275 references] PubMed

Lok AS, McMahon BJ. Corrections to AASLD guidelines on chronic hepatitis B. Hepatology 2007 Jun;45(6):1347. [1 reference] PubMed

GUIDELINE STATUS
This is the current release of this guideline.

This guideline updates a previous version: Lok AS, McMahon BJ. Chronic hepatitis B. Alexandria (VA): American Association for the Study of Liver Diseases; 2004. 25 p.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references drugs for which important revised regulatory information has been released:

August 16, 2007, Baraclude (Entecavir): Revisions to the prescribing information for Baraclude to indicate that the drug is not recommended for HIV/hepatitis B virus (HBV) co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) due to the potential for the development of HIV resistance.

abrir aquí para acceder al documento NGC AHRQ completo:
(1) Chronic hepatitis B. (2) Corrections to AASLD guidelines on chronic hepatitis B.